e-learning
resources
Barcelona 2013
Sunday, 08.09.2013
Systemic and airway biomarkers in respiratory diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Microarray profiling of COPD patients versus non-COPD smokers reveals possible disease biomarkers
D. Kampas, E. Neofytou, N. Soulitzis, D. Dermitzaki, N. Siafakas, E. Tzortzaki (Heraklion, Greece)
Source:
Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases
Session:
Systemic and airway biomarkers in respiratory diseases
Session type:
Thematic Poster Session
Number:
845
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Kampas, E. Neofytou, N. Soulitzis, D. Dermitzaki, N. Siafakas, E. Tzortzaki (Heraklion, Greece). Microarray profiling of COPD patients versus non-COPD smokers reveals possible disease biomarkers. Eur Respir J 2013; 42: Suppl. 57, 845
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Metabolomics identifies biomarkers of exacerbations in smokers with and without COPD
Source: Virtual Congress 2020 – Inflammatory pathways in chronic airway diseases
Year: 2020
Comparison of breath VOCs collected from controls, healthy smokers, smokers with COPD, and ex-smokers with COPD at two sites
Source: International Congress 2015 – Exhaled biomarkers in children and adults with airways disease
Year: 2015
Sputum biomarkers of inflammation in smokers and subjects with COPD
Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases
Year: 2013
Proteomic analysis of plasma from COPD patients and smoking control subjects
Source: Annual Congress 2007 - Novel therapeutic targets and disease markers in pulmonary pathology
Year: 2007
Differences in COPD: Smokers versus non smokers
Source: International Congress 2015 – Asthma and COPD: overlap and exacerbations
Year: 2015
Proteinase-inhibitor system state in patients with COPD
Source: International Congress 2015 – COPD: chronic disease and comorbidities
Year: 2015
Metabolomic signature in COPD. Plasma and lung tissue comparison identify sphingolipids as potential biomakers
Source: International Congress 2014 – Markers
Year: 2014
The effect of smoking on the activity of inflammatory markers in patients with COPD
Source: Annual Congress 2013 –Tobacco use in different countries: crisis to disease
Year: 2013
Role of inflammatory biomarkers in COPD
Source: International Congress 2016 – Systemic biomarkers
Year: 2016
Comparison between COPD and non-COPD patients with established cardiovascular diseases: A profiling of respiratory symptoms and functional status
Source: Annual Congress 2010 - Comorbidity in obstructive airway disease
Year: 2010
Characterization and functional progression of COPD in young adults (early COPD)
Source: Annual Congress 2013 –Diagnosis and management of respiratory diseases
Year: 2013
What is the best biomarker of COPD stability?
Source: International Congress 2015 – COPD: chronic disease and comorbidities
Year: 2015
Identification of oxidative stress markers and their association with inflammation in smokers and early chronic obstructive pulmonary disease (COPD)
Source: International Congress 2016 – Hospitalisation and comorbidities in chronic lung diseases
Year: 2016
Plasma metabolomic signature in COPD patients: Associations to proteomic profile and clinical outcomes
Source: Annual Congress 2013 –COPD mechanisms
Year: 2013
Serum BNP levels in COPD, asthma-COPD-overlap-syndrome, smokers and never-smokers
Source: International Congress 2016 – Systemic biomarkers
Year: 2016
Pro-surfactant protein B, a promising BAL biomarker of COPD progression in heavy smokers, is increased by budesonide/formoterol short-term therapy
Source: Annual Congress 2013 –Biomarkers in asthma and COPD
Year: 2013
A multimarker approach to identify atherosclerosis in COPD
Source: International Congress 2014 – Markers
Year: 2014
LSC - 2020 - Longitudinal effect of smoking cessation on transcriptomics and epigenetics in the airways of COPD patients and asymptomatic controls
Source: Virtual Congress 2020 – Intercellular communication in tissue remodelling of chronic lung diseases
Year: 2020
Mathematical model to predict the risk of future exacerbations in non-smoking patients with COPD
Source: International Congress 2016 – Phenotyping and monitoring airway diseases
Year: 2016
Endothelial microparticles in sputum of COPD patients: A potential biomarker of disease
Source: International Congress 2015 – Systemic and airway biomarkers
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept